title: Ustekinumab in Pediatric Crohn Disease Patients.
abstract: We describe the use of ustekinumab for 4 patients with pediatric Crohn disease treated at the Seattle Children's Hospital Inflammatory Bowel Disease Center.
  
  
  
  A retrospective chart review was done to identify patients' clinical data, disease phenotype, treatment history, and laboratory and growth parameters before treatment with ustekinumab and at last follow-up. Adverse events while on ustekinumab were also recorded.
  
  
  
  Four adolescent patients with Crohn disease at our center received ustekinumab. All had previously received corticosteroids, methotrexate, azathioprine/6-mercaptopurine, and both infliximab and adalimumab. Patients had varying disease phenotypes. Ages at ustekinumab initiation were 12, 13, 16, and 17 years. Weight ranged from 40.5 to 57.8 kg, mean 49.5 kg. Two patients showed clinical response and remain on ustekinumab. Two patients discontinued therapy because of continued symptoms and disease complications and required multiple hospitalizations.
  
  
  
  Ustekinumab was used in 4 children with pediatric Crohn disease with 2 of 4 patients showing clinical response (1 with persistently elevated C-reactive protein). A prospective study is needed to define its efficacy, safety, and placement in managing pediatric Crohn disease in the future.
authors: *University of Rochester, Rochester, NY †University of Iowa, Iowa City ‡Inflammatory Bowel Disease Center, Seattle Children's Hospital, Seattle, WA.
authors: Casey
authors: C
authors: Bishop
authors: Hayley
authors: H
authors: Simon
authors: David
authors: D
authors: Suskind
authors: Dale
authors: D
authors: Lee
authors: Ghassan
authors: G
authors: Wahbeh
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000032:analysis; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D010641:Phenotype; D012189:Retrospective Studies; D012720:Severity of Illness Index; D000069549:Ustekinumab / Q000008:administration & dosage*
chemical_list: D000911:Antibodies, Monoclonal; D002097:C-Reactive Protein; D000069549:Ustekinumab